Agilent and Lipomics collaborate on lipid biomarker assays

Published: 1-Apr-2007

Agilent and Lipomics are to collaborate on the development of diagnostic assays, combining Agilent analytical platforms with Lipomics" expertise in biomarker discovery and validation.


Agilent and Lipomics are to collaborate on the development of diagnostic assays, combining Agilent analytical platforms with Lipomics" expertise in biomarker discovery and validation.

The assays will focus on metabolic diseases, a family of related disorders driven in large part by subtle, long-term dysregulation of lipid metabolism.

Lipomics Technologies provides quantitative, diagnostically accurate measurements of more than 1,500 metabolites, allowing comprehensive profiling of whole-body lipid metabolism. The company's quantitative methods and expertise in lipid biology drive development of clinically relevant diagnostic and research assays.

You may also like